Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Significant Liver Injury During Hospitalization for COVID-19 Is Not Associated With Liver Insufficiency or Death

Michael Chew,*+,a Zeyu Tang,§,a Christopher Radcliffe,§ Dennis Caruana,§ Natty Doolicho,§ Maria M. Ciarleglio,‖ Yanhong Deng,‖ and Guadalupe Garcia-Tsao*++,

*Digestive Diseases Section, §Yale University School of Medicine, New Haven, Connecticut; ‡VA–Connecticut Healthcare System, West Haven, Connecticut; ‖Yale Center for Analytical Sciences, Yale University School of Public Health, New Haven, Connecticut

BACKGROUND & AIMS: Coronavirus-19 disease (COVID-19) is associated with hepatocellular liver injury of uncertain significance. We aimed to determine whether development of significant liver injury during hospitalization is related to concomitant medications or processes common in COVID-19 (eg, ischemia, hyperinflammatory, or hypercoagulable states), and whether it can result in liver failure and death.

METHODS: There were 834 consecutive patients hospitalized with COVID-19 who were included. Clinical, medication, and laboratory data were obtained at admission and throughout hospitalization using an identified database. Significant liver injury was defined as an aspartate aminotransferase (AST) level 5 or more times the upper limit of normal; ischemia was defined as vasopressor use for a minimum of 2 consecutive days; hyperinflammatory state was defined as
Results:

A total of 105 (12.6%) patients developed significant liver injury. Compared with patients without significant liver injury, ischemia (odds ratio [OR], 4.3; range, 2.5–7.4; P < .0001) and tocilizumab use (OR, 3.6; range, 1.9–7.0; P = .0001) were independent predictors of significant liver injury. Although AST correlated closely with alanine aminotransferase (R = 0.89) throughout hospitalization, AST did not correlate with the international normalized ratio (R = 0.10) or with bilirubin level (R = 0.09). Death during hospitalization occurred in 136 (16.3%) patients. Multivariate logistic regression showed that significant liver injury was not associated with death (OR, 1.4; range, 0.8–2.6; P = .2), while ischemic (OR, 2.4; range, 1.4–4.0; P = .001), hypercoagulable (OR, 1.7; range, 1.1–2.6; P = .02), and hyperinflammatory (OR, 1.9; range, 1.2–3.1; P = .02) disease states were significant predictors of death.

Conclusions:

Liver test abnormalities known to be associated with COVID-19 are secondary to other insults, mostly ischemia or drug-induced liver injury, and do not lead to liver insufficiency or death.

Keywords: COVID-19; Liver Injury; Hepatitis.
race, ethnicity, history of diabetes, hypertension, coronary artery disease, obesity, obstructive lung disease, congestive heart failure, and underlying liver disease. Comorbidities were determined based on International Classification of Diseases 9th revision and 10th revision codes. Relevant laboratory tests were collected at admission and throughout hospitalization. The administration and timing of relevant medications at any time during hospitalization, including vasopressors and potentially hepatotoxic drugs (eg, tocilizumab, antibiotics, lopinavir/ritonavir), were collected. Time of admission was subtracted from time-to-order to determine the time elapsed from hospital admission to each order instance. All admission data, medication data, laboratory values, and laboratory dates (initial, peak, and most recent) were verified manually by chart review (M.C., Z.T., C.R., N.D., and D.C.).

Definitions

Liver test abnormalities were defined based on the Yale New Haven Hospital laboratory reference range standards (Supplementary Table 1). Because an increase in AST levels is the most common abnormality in COVID-19 and based on American College of Gastroenterology guidelines,15 we defined significant liver injury as an AST level increased by 5 or more times the ULN at any time during hospitalization.

In addition to medications, conditions/disease states that occur commonly during the course of COVID-19 and that could cause liver injury were defined as follows: ischemic injury was defined as the use of vasopressors (norepinephrine, vasopressin, dopamine, and phenylephrine) for at least 2 consecutive days; a hyperinflammatory state was defined as any high-sensitivity C-reactive protein (hs-CRP) level of 100 mg/L or higher; and a hypercoagulable state was defined as any D-dimer level of 5 mg/L or higher.

Statistical Analysis

Descriptive statistics were summarized using medians and ranges for continuous variables and counts and proportions for categoric variables.

To investigate factors associated independently with significant liver injury, relevant medications or disease states associated significantly with an AST level greater than 5 times the ULN at any time during hospitalization on univariate analysis (by the Fisher exact test for categoric variables, by the Wilcoxon rank-sum test for continuous variables) then were analyzed using a multivariable logistic regression model (excluding variables that intercorrelated significantly). As sensitivity analyses, both models were adjusted further for potential confounders, specifically age, sex, race, body mass index (BMI), and comorbidities. A sensitivity analysis using an ALT level 5 or more times the ULN also was performed.

Within-patient correlations between changes from baseline in AST vs ALT, INR, AP, TBIL, CRP, and D-dimer throughout hospitalization were explored using bivariate longitudinal mixed-effects regression models. Because of the highly skewed nature of laboratory values, log-transformed laboratory values were used. For reference, a log AST of 4.0 equals an AST of 55 IU/mL. Changes from baseline in these log-transformed variables over the hospitalization period were plotted for several representative patients. Trends in log-transformed AST over time were examined between ischemia status and tocilizumab treatment status using mixed-effects models and the trajectory plots of log-transformed AST.

P values less than or equal to .05 were considered statistically significant. All analyses were conducted using SAS (version 9.4; Cary, NC) and R (version 3.6.2; Vienna, Austria).

Results

Characteristics of the 834 patients included in the study are shown in Table 1. The median age was 68 years, 48% were male, the median BMI was 28.2, and 40% were obese. Only 51 patients (6.1%) had underlying liver disease (mostly without cirrhosis). The median length of hospital stay was 10 days (range, 0–83 d), with 8 patients...
still hospitalized at the end of the follow-up evaluation. Of the 834 patients, 273 (33%) were placed on steroids; 259 (31%) required admission to step-down units or intensive care units (ICUs); 133 (16%) received at least 1 dose of vasopressors, with 102 (12%) of them remaining on vasopressors for at least 2 days; and 108 (13%) were intubated. All 102 patients requiring vasopressors for at least 2 days were in step-down units/ICUs, 99 (97%) were on at least 1 antibiotic, 93 (91%) were intubated, and 77 (76%) were on steroids. As shown in Supplementary Table 2, 13 different classes of antibiotics were used, the most common being β-lactams, followed by vancomycin (mostly in combination with piperacillin/tazobactam). COVID-19–specific treatments included hydroxychloroquine in 725 (87%), tocilizumab in 502 (60%), and only 51 patients (6%) received remdesivir.

### Table 1. Baseline Characteristics and Data on Admission Stratified by Absence or Presence of Significant Liver Injury (AST >5× ULN) During Hospitalization

| Characteristic                      | Overall (834) | Univariate | Ast <5× ULN (N = 729) | Ast >5× ULN (N = 105) | P value |
|-------------------------------------|---------------|------------|-----------------------|-----------------------|---------|
|                                     |               |            | AST <5× ULN (N = 729) | AST >5× ULN (N = 105) |         |
| Age, y                              | 68.0 (20.0–103.0) | 70.0 (20.0–98.0) | 60.0 (21.0–103.0) | <.001 |
| Sex                                 |               |            |                       |                       |         |
| Male, %                             | 47.6          | 45.3       | 63.8                  |                       | <.001  |
| Female, %                           | 52.4          | 54.7       | 36.2                  |                       |         |
| Race, N (%)                         |               |            |                       |                       | <.001  |
| White                               | 459 (55.0)    | 421 (57.7) | 38 (36.2)             |                       |         |
| Black                               | 240 (28.8)    | 207 (28.4) | 33 (31.4)             |                       |         |
| Asian or Pacific Islander           | 14 (1.7)      | 12 (1.7)   | 2 (1.9)               |                       |         |
| Other                               | 121 (14.5)    | 89 (12.2)  | 32 (30.5)             |                       |         |
| Ethnicity: Hispanic or Latino       | 147 (17.6)    | 111 (15.2) | 36 (34.3)             |                       | <.001  |
| Median BMI, kg/m² (range)           | 28.2 (14.6–73.9) | 28.1 (14.6–73.9) | 28.3 (17.0–56.8) | .2    |
| BMI >30 kg/m²                       | 336 (40.3)    | 290 (39.8) | 46 (43.8)             | .4                  |
| Comorbidities, N (%)                |               |            |                       |                       |         |
| Coronary artery disease             | 97/716 (13.5) | 85/625 (13.6) | 12/91 (13.2)         | .9                  |
| Hypertension                        | 631 (75.6)    | 562 (77.1) | 69 (65.7)             | .01                 |
| Congestive heart failure            | 249 (29.8)    | 233 (31.9) | 16 (15.2)             | <.001               |
| Chronic lung disease                | 277 (33.2)    | 252 (34.6) | 25 (23.8)             | .03                 |
| Diabetes                            | 357 (42.8)    | 322 (44.2) | 35 (33.3)             | .04                 |
| Pre-existing liver disease, N (%)   | 51 (6.1)      | 42 (5.7)   | 9 (8.6)               | .3                  |
| No cirrhosis                        | 39 (4.5)      | 30 (4.1)   | 8 (7.6)               |                     |
| Compensated cirrhosis               | 10 (1.2)      | 9 (1.2)    | 1 (0.1)               |                     |
| Decompensated cirrhosis             | 3 (0.3)       | 3 (0.4)    | 0                     |                     |
| Admission liver biochemistries      |               |            |                       |                       |         |
| AST, U/L                            | 40.0 (9.0–3054.0) | 37.0 (9.0–162.0) | 89.0 (16.0–3054.0) | <.001  |
| Alanine aminotransferase, U/L       | 26.0 (4.0–904.0) | 24.0 (4.0–281.0) | 57.0 (9.0–904.0) | <.001  |
| Total bilirubin, mg/dL              | 0.4 (0.1–5.1) | 0.4 (0.1–5.1) | 0.5 (0.1–4.0)        | .03                 |
| Alkaline phosphatase, U/L           | 74.5 (22.0–838.0) | 74.0 (22.0–838.0) | 79.0 (32.0–417.0) | .4                  |
| Albumin, mg/dL                      | 3.5 (1.7–5.4) | 3.6 (1.8–5.4) | 3.5 (1.7–4.7)        | .09                 |
| INR                                 | 1.0 (0.8–9.9) | 1.0 (0.8–9.9) | 1.0 (0.8–5.4)        | .1                  |
| Inflammatory markers                |               |            |                       |                       |         |
| hs-CRP, mg/L (N = 829)              | 76.9 (0.2–445.0) | 71.7 (0.2–445.0) | 114.2 (1.8–301.0) | <.001  |
| Ferritin, ng/mL (N = 820)           | 531.5 (7.0–9365.0) | 480.0 (7.0–8903.0) | 1017.0 (19.0–9365.0) | <.001  |
| Fibrinogen, mg/dL (N = 812)         | 509.5 (115.0–861.0) | 496.0 (115.0–861.0) | 596.0 (217.0–861.0) | <.001  |
| D-Dimer, mg/dL (N = 820)            | 1.0 (0.2–35.2) | 1.0 (0.2–35.2) | 1.1 (0.2–33.9)       | .7                  |
| Cytokines                           |               |            |                       |                       |         |
| IL6 pg/mL (N = 774)                 | 6.0 (945.0)   | 6.0 (931.0) | 9.0 (4045.0)          | .03                 |
| IL8 pg/mL (N = 782)                 | 4.0 (4.0–192.0) | 4.0 (4.0–210) | 4.0 (4.0–192.0) | .6                  |
| IL10 pg/mL (N = 778)                | 4.0 (4.0–213.0) | 4.0 (4.0–213.0) | 4.0 (4.0–132.0) | .8                  |
| IFN-Y pg/mL (N = 779)               | 4.0 (4.0–130.0) | 4.0 (4.0–130.0) | 4.0 (4.0–30.0)       | .5                  |
| TNF-α pg/mL (N = 781)               | 4.0 (4.0–267.0) | 4.0 (4.0–267.0) | 4.0 (4.0–158.0)       | .8                  |

NOTE. Values are reported as median (ranges) unless otherwise specified.
AST, aspartate aminotransferase; BMI, body mass index; hs-CRP, high-sensitivity C-reactive protein; IFN, interferon; IL, interleukin; INR, international normalized ratio; TNF, tumor necrosis factor; ULN, upper limit of normal.
On admission, AST level was abnormal in 521 patients (62.5%), ALT level was abnormal in 281 patients (33.7%), 99 patients (11.9%) had an abnormal AP level, and 26 patients (3.1%) had an abnormal TBIL level (Supplementary Table 3). Consistent with other studies, AST level was higher than ALT level. In most patients, abnormalities were mild at 1 to 2 times the ULN. A median of 7 liver panel tests (range, 1–136 liver panel tests) per patient were available, with only 46 patients having a single set of tests. The median time to peak AST level for the entire cohort was 3 days (interquartile range, 1–6 d) after admission. AST level normalized in 222 patients (43%) in a median period of 4.4 days (range, 0–29.8 d). There was a strong correlation ($R = 0.89$) between changes in AST and changes in ALT levels over time (Figure 1). However, only minimal correlation was observed over time between changes in AST level and changes in TBIL level ($R = 0.09$), between AST and AP level ($R = 0.15$), or between AP and TBIL level ($R = 0.24$).

**Factors associated with the development of significant liver injury during hospitalization.** Significant liver injury was observed in only 25 patients (3%) at the time of admission, however, it developed during...
hospitalization in 105 patients (12.6%) (Supplementary Table 3). Patients with significant liver injury were younger, more likely to be male, black or Hispanic, and have higher aminotransferase levels at admission (Table 1).

As shown in Table 2, patients with significant liver injury were sicker, as indicated by higher rates of ICU admission, intubation, and treatment with steroids, vasopressors, and tocilizumab. Patients with pre-existing liver disease were not more likely to develop significant liver injury. On multivariable analysis, an ischemic state and tocilizumab use were the only 2 independent predictors of significant liver injury (Table 2). The same 2 predictors were identified when using an ALT level 5 or more times the ULN as a marker of severe liver injury (Supplementary Table 4). Sensitivity analyses that further adjusted the multivariable model for potential confounders of age, sex, race, and BMI gave identical conclusions (data not shown).

To emphasize the relationship between significant liver injury and ischemia, in 29 patients with AST values for 3 time periods (up to 2 days before, during, and up to 4 days after vasopressor discontinuation), the peak AST level was higher during vasopressor use (log 4.72), compared with before (log 4.35) or after vasopressors (log 4.19) \( (P = .003) \) (Supplementary Figure 2).

**Figure 2.** Correlation between aspartate aminotransferase (AST) (red) and international normalized ratio (INR) (blue) throughout hospitalization in 20 randomly selected patients. There was no clear correlation in the overall population (\( R = 0.10 \)).
Furthermore, in 41 patients with paired AST values before and during vasopressor use the peak AST level was higher during vasopressor use (log 4.79 vs log 4.47; \( P = .018 \)), and in 76 patients with paired AST values during and after vasopressor use the peak AST level was higher during vasopressor use (log 4.7 vs log 4.32; \( P < .001 \)).

To emphasize the relationship between AST level and tocilizumab use, in 426 patients with paired AST values (before and after tocilizumab), peak AST level was higher after tocilizumab, both in the 2-week period (log 4.45) and in the 4-week period (log 4.48) after its use compared with peak AST value before tocilizumab (log 3.91) (\( P < .001 \) for both comparisons).

**Factors associated with death.** A total of 136 patients (16.3%) died from COVID-19 during hospitalization. Compared with survivors, those who died had higher rates of ICU admission, intubation, management with steroids, vasopressors, and tocilizumab (Table 3). Patients who died also were more likely to have a hypercoagulable or hyperinflammatory state. Patients with pre-existing liver disease were not more likely to die. On multivariable analysis, vasopressor use (ischemia), a hyperinflammatory state, and a hypercoagulable state were independent predictors of death. Significant liver injury (AST \( \geq 5 \times \) ULN) was not an independent predictor of death (Table 3). This finding was confirmed in sensitivity analyses that adjusted the multivariable model for baseline characteristics (age, sex, race, BMI, and comorbidities) (Supplementary Table 5) and in an analysis excluding 46 patients with a single admission value of AST (Supplementary Table 6). The lack of an association with death also was identified when using an ALT value 5 or more times the ULN as a marker of severe liver injury (Supplementary Table 7).

The AST level throughout hospitalization did not correlate with any of the following: hs-CRP (R = 0.04), D-dimer (R = 0.15), TBIL (R = 0.09) or, importantly, with the INR (R = 0.10) (Figure 2). Of the 105 patients with significant liver injury, there were only 8 patients (7.6%) in whom the peak AST level was associated with an INR greater than 1.5 as an indicator of liver failure (encephalopathy was not evaluated because all of these patients were sedated). Characteristics of these patients are shown in Supplementary Table 8.

There was no significant difference in hospitalization status for those who were discharged, still admitted, or died at the time of follow-up evaluation (\( P = .3 \)) between

### Table 2. Events/Disease States Occurring Throughout Hospitalization Associated With Significant Liver Injury (AST \( \geq 5 \times \) ULN)

| Characteristic                  | Overall (834) | Univariate | Multivariate |
|---------------------------------|---------------|------------|--------------|
|                                 | AST <5× ULN   | AST ≥5× ULN| P value      |
|                                 | (N = 729)     | (N = 105)  | Odds ratio   | 95% CI | P value |
| **Length of stay, d**           |               |            |              |        |         |
| 10 (0–83)                       | 10 (0–77)     | 13 (1–83)  | <.001        | –      | –       | –       |
| **Hospitalization status, N (%)**|               |            |              |        |         |         |
| Discharged                      | 690 (82.7)    | 608 (83.4) | 82 (78.1)    | .3     | –       | –       |
| Still admitted                  | 8 (1.0)       | 6 (0.8)    | 2 (1.9)      |        | –       | –       |
| Deceased                        | 136 (16.3)    | 115 (15.8) | 21 (20.0)    |        | –       | –       |
| **Conditions during follow-up period, N (%)** |               |            |              |        |         |         |
| Intensive care unit             | 259 (31.1)    | 196 (26.9) | 63 (60.0)    | <.001  | –       | –       |
| Venous thromboembolism          | 4 (0.5)       | 4 (0.5)    | 0            | 1.0    | –       | –       |
| Intubation                      | 108 (12.9)    | 62 (8.5)   | 46 (43.8)    | <.001  | –       | –       |
| **Medications, N (%)**          |               |            |              |        |         |         |
| Antibiotics                     | 543 (65.1)    | 468 (64.2) | 75 (71.4)    | .1     | –       | –       |
| Hydroxychloroquine              | 725 (86.9)    | 628 (86.1) | 97 (92.4)    | .08    | –       | –       |
| Tocilizumab                     | 502 (60.2)    | 410 (56.2) | 92 (87.6)    | <.001  | 3.6     | 1.9–7.0 | .0001 |
| Remdesivir                      | 51 (6.1)      | 40 (5.5)   | 11 (10.5)    | .05    | –       | –       |
| Steroid                         | 273 (32.7)    | 224 (30.7) | 49 (46.7)    | <.001  | 0.7     | 0.4–1.2 | .2     |
| Statin                          | 343 (41.1)    | 305 (41.8) | 38 (36.2)    | .3     | –       | –       |
| NSAID                           | 369 (44.2)    | 315 (43.2) | 54 (51.4)    | .1     | –       | –       |
| **Disease states**              |               |            |              |        |         |         |
| Ischemic                        | 102 (12.2)    | 60 (8.2)   | 92 (40.0)    | <.001  | 4.3     | 2.5–7.4 | <.0001 |
| Hyperinflammatory               | 484 (58.4)    | 401 (55.4) | 83 (79.0)    | <.001  | 1.5     | 0.9–2.6 | .1     |
| Hypercoagulable                 | 251 (30.6)    | 197 (27.6) | 54 (51.4)    | <.001  | 1.3     | 0.8–2.2 | .3     |

**NOTE.** Values are reported as median (ranges) unless otherwise specified. Ischemic state was defined as vasopressor use for at least 2 days; hyperinflammatory state was defined as any high-sensitivity C-reactive protein value >100 mg/L; hypercoagulable state was defined as any D-dimer level ≥5 mg/L. Because all patients on vasopressors were in the intensive care unit and most were intubated/on antibiotics, these variables were not entered into the multivariable model. Remdesivir was not included because only 51 patients received it.

AST, aspartate aminotransferase; NSAID, nonsteroidal anti-inflammatory drug; ULN, upper limit of normal.
patients with and without significant liver injury during hospitalization (Table 2).

**Discussion**

The development of liver test abnormalities during hospitalization for COVID-19 were frequent. However, the pathophysiology of these abnormalities and their relationship to increased mortality, vis-à-vis concomitant confounders (ischemia, medications, and hyper-inflammatory and/or hypercoagulable states), remains unclear. Abnormalities were predominantly hepatocellular and consistently showed AST values higher than ALT values. This is unlike most viral hepatitis (hepatitis A, B, or C) in which ALT value is higher than AST value. Conditions in which AST value is higher than ALT value are those that predominantly affect the hepatic lobe and consistently showed AST values higher than ALT values. This is unlike most viral hepatitides (hepatitis B or C) in which ALT value is higher than AST value. Conditions in which AST value is higher than ALT value are those that predominantly affect the hepatic lobe and consistently showed AST values higher than ALT values. This is unlike most viral hepatitides (hepatitis B or C) in which ALT value is higher than AST value.

Table 3. Events/Disease States Occurring During Hospitalization Associated With Death

| Characteristic                        | Overall (834) | Univariate Alive (N = 698) | Multivariate | P value |
|--------------------------------------|---------------|--------------------------|--------------|---------|
| Conditions during follow-up period, N (%) |               |                           |              |         |
| Intensive care unit                  | 259 (31.1)    | 184 (26.4)               | 75 (55.1)    | <.001   |
| Venous thromboembolism               | 4 (0.5)       | 2 (0.3)                  | 2 (1.5)      | .1      |
| Intubation                           | 108 (12.9)    | 70 (10.0)                | 38 (27.9)    | <.001   |

| Medications, N (%)                   |               |                           |              |         |
|--------------------------------------|---------------|--------------------------|--------------|---------|
| Antibiotics                          | 543 (65.1)    | 430 (61.6)               | 113 (83.1)   | <.001   |
| Hydroxychloroquine                   | 725 (86.9)    | 617 (88.4)               | 108 (79.4)   | .004    |
| Tocilizumab                           | 502 (60.2)    | 406 (58.2)               | 96 (70.6)    | .007    |
| Remdesivir                           | 51 (6.1)      | 38 (5.4)                 | 13 (9.5)     | .07     |
| Steroid                              | 273 (32.7)    | 207 (29.6)               | 66 (48.5)    | <.001   |
| Statin                               | 343 (41.1)    | 298 (42.7)               | 45 (33.1)    | .04     |
| NSAID                                | 369 (44.2)    | 315 (45.1)               | 54 (39.7)    | .2      |

| Disease states, N (%)                |               |                           |              |         |
|--------------------------------------|---------------|--------------------------|--------------|---------|
| AST ≥5× ULN                          | 105 (12.6)    | 84 (12.0)                | 21 (15.4)    | .3      |
| Ischemic                             | 102 (12.2)    | 69 (9.9)                 | 33 (24.3)    | <.001   |
| Hyperinflammatory                    | 484 (58.4)    | 383 (55.0)               | 101 (76.0)   | <.001   |
| Hypercoagulable                      | 251 (30.6)    | 186 (27.0)               | 65 (50.0)    | <.001   |

**NOTE.** Values are reported as median (ranges) unless otherwise specified. Ischemic state = vasopressor use for at least 2 days; hyperinflammatory state = any high-sensitivity C-reactive protein value ≥100 mg/L; hypercoagulable state = any D-dimer ≥5 mg/L. Because all patients on vasopressors were in the intensive care unit and most were intubated and on antibiotics and/or hydroxychloroquine, these variables were not entered in the multivariable model.

AST, aspartate aminotransferase; CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug; ULN, upper limit of normal.

Aminotransferase abnormalities during COVID-19 are commonly mild, with only 20% or so of patients developing increases in AST values of 5 or more times the ULN. The objectives of this study were to determine whether liver injury during hospitalization is more reflective of concomitant factors than direct liver injury by SARS-CoV-2, and whether this liver injury is related independently to death in patients with COVID-19.

Several studies have looked specifically at abnormalities in liver tests during hospitalization. They were mostly rapid communications performed at the beginning of the pandemic that relied on deidentified data obtained from administrative databases without confirmation from medical record review and using admission data and/or peak abnormalities during hospitalization. Similar to our study, all of the studies showed that aminotransferase abnormalities were more marked in patients with severe COVID-19 (using different definitions of severity). Although a small study by Bloom et al could not find any factor that would predict significant liver injury, larger studies identified peak ferritin and peak interleukin (IL)6 levels; age, male sex, fever, dyspnea, gastrointestinal symptoms, antibiotics, steroid, leukocyte, and platelet counts; or pre-admission AST and tocilizumab levels. Regarding factors associated with death, the study by Phipps et al showed that age, diabetes, intubation, and peak ALT levels were independent predictors of death, while the study by Lei et al showed that, compared with other liver tests, peak
AST level was associated with the highest risk of death. However, variables were analyzed in these studies without accounting for intercorrelations among them.

Our study correlated pathophysiologically relevant disease states during COVID-19 that potentially could be associated with significant liver injury during hospitalization and established intercorrelations among predictive variables. We defined significant liver injury using an AST value more than 5 times the ULN and, although one can argue that the source of AST is the muscle, we showed a very close correlation between AST and ALT values and previous data showing a lack of correlation between AST and creatine kinase values, minimize this possibility for the majority of cases.

Ischemic liver injury results from a global decrease in blood flow to the liver associated with hypotension and therefore we considered vasopressor use as a surrogate for ischemic liver injury. Because most of the patients on vasopressors also were intubated, this also would add to the possibility of ischemic damage resulting from hypo-oxygenation. Initially, we considered any use of vasopressors (in 133 patients) during hospitalization but realized that some patients had received only 1 dose of vasopressors and therefore changed our definition to include 102 patients who had been on vasopressors for at least 2 consecutive days. The so-defined ischemic state was the most important predictor of significant liver injury in our study and a significant predictor of death (independent of AST value). Of note, results using the original definition of ischemia were not different (results not shown).

It also has been proposed that the liver injury could be from a hyperinflammatory state that is characterized by immune dysregulation and hypercytokinemia, resulting in cytokine storm syndrome. Although IL6 increases were only modest in our study and not at levels described in other cytokine storm syndromes such as in chimeric antigen T-cell therapy in which it exceeds 1000 pg/mL, we decided to incorporate a marker of hyperinflammation given the finding of high ferritin (another marker of inflammation) as a predictor of liver injury in the study by Phipps et al. However, because there was a significant correlation between ferritin, IL6, and hs-CRP values, we defined it solely as a hs-CRP level greater than 100 mg/L. Although hs-CRP levels did not correlate with AST levels throughout hospitalization and was not predictive of significant liver injury, the inflammatory state was predictive of death, as has been shown in other studies.

Another potential cause of liver injury is a hypercoagulable state, which also has been associated with COVID-19. Studies have shown increased markers for endothelial cell and platelet activation in patients with severe disease, potentially resulting in microthrombi that could affect liver blood flow. We initially defined the hypercoagulable state as increased D-dimer and fibrinogen levels, however, because these tests also correlated significantly, we defined it solely as a D-dimer level of 5 mg/L or higher throughout hospitalization. Although the hypercoagulable state was not predictive of significant liver injury, it was associated with mortality.

To investigate drug-induced liver injury we looked at all medications used during hospitalization. Drugs commonly used in patients with COVID-19 known to cause drug-induced liver injury are tocilizumab, lopinavir/ritonavir, hydroxychloroquine, remdesivir, and antibiotics. Because most patients on pressors were on antibiotics and the classes of antibiotics varied, they were not incorporated in multivariate models. On univariate analysis both tocilizumab and remdesivir were significantly more common in patients with significant liver injury. Remarkably, and similar to the study by Hundt et al, we found tocilizumab use to be an independent predictor of significant liver injury, but not of death.

One of the main issues is the association between significant liver injury during hospitalization and death in patients with COVID-19. We found that significant liver injury was not an independent predictor of death, whereas disease states associated with COVID-19 (ischemic, hyperinflammatory, and hypercoagulable) were predictive. Furthermore, AST levels did not correlate with INR (Figure 2), indicating that abnormalities were not associated with liver insufficiency. In detailing the characteristics of only 8 patients with AST levels more than 15 times the ULN associated with an INR greater than 1.5, all had an abnormal serum creatinine concentration (range, 1.8–7.1), which suggests the liver injury was part of a multiorgan failure state.

In conclusion, although direct viral injury cannot be entirely excluded, our study indicates that concomitant factors, mainly ischemia and drug-induced liver injury, play a major role in the pathogenesis of significant liver injury during COVID-19. Perhaps more importantly, this liver injury is not associated directly with liver insufficiency or death.

**Supplementary Material**

Note: To access the supplementary material accompanying this article, visit the online version of *Clinical Gastroenterology and Hepatology* at [www.cgjhjournal.org](http://www.cgjhjournal.org), and at [https://doi.org/10.1016/j.cgh.2021.05.022](https://doi.org/10.1016/j.cgh.2021.05.022).

**References**

1. Pirola CJ, Sookoian S. SARS-CoV-2 virus and liver expression of host receptors: putative mechanisms of liver involvement in COVID-19. Liver Int 2020;40:2038–2040.

2. Lagana SM, Kudose S, Iuga AC, et al. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. Mod Pathol 2020; 33:2147–2155.

3. Sonzogni A, Previtali G, Seghezzi M, et al. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. Liver Int 2020;40:2110–2116.
4. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708–1720.
5. Sultan S, Lim JK, Altayar O, et al. AGA Institute rapid recommendations for gastrointestinal procedures during the COVID-19 pandemic. Gastroenterology 2020;158:739–758.
6. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systemic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:667–678.
7. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323:2052–2059.
8. Phipps MM, Barraza LH, LaSota ED, et al. Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large US cohort. Hepatology 2020;72:807–817.
9. Huang H, Chen S, Li H, et al. The association between markers of liver injury and mortality in COVID-19. Hepatology 2020;72:1169–1176.
10. Lei F, Liu YM, Zhou F, et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology 2020;72:389–398.
11. Ponziani FR, Del Zompo F, Nesci A, et al. Liver functional abnormality. Clin Gastroenterol Hepatol 2020;18:1561–1566.
12. Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol 2020;18:1059–1068.
13. Bloom PP, Meyerowitz EA, Reinus Z, et al. Liver biochemistries in hospitalized patients with COVID-19. Hepatology 2021; 73:890–900.
14. Huang H, Chen S, Li H, et al. The association between markers of liver injury and clinical outcomes in patients with COVID-19 in Wuhan. Aliment Pharmacol Ther 2020;52:1051–1059.
15. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation and management of abnormal liver chemistries. Am J Gastroenterol 2017; 112:18–35.
16. Kasarala G, Tillmann HL. Standard liver tests. Clin Liver Dis (Hoboken) 2016;8:13–18.
17. Wunder P, Epstein M, Bernstein D. COVID-19 presenting as acute hepatitis. Am J Gastroenterol 2020;115:941–942.
18. Melquist S, Estepp K, Aleksandrovich Y, et al. COVID-19 presenting as fulminant hepatic failure: a case report. Medicine (Baltimore) 2020;99:e22818.
19. Strassburg CP. Gastrointestinal disorders of the critically ill. Shock liver. Best Pract Res Clin Gastroenterol 2003; 17:369–381.
20. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation and management of abnormal liver chemistries. Am J Gastroenterol 2017; 112:18–35.
21. Manson JJ, Crooks C, Naja M, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol 2020; 2:e594–e602.
22. Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 2020; 7:e575–e582.
23. McConnell M, Kawaguchi N, Kondo R, et al. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. Journal of Hepatology 2021: https://doi.org/10.1016/j.jhep.2021.04.050; In press.
24. Singhania N, Bansal S, Nimmaotdi DP, et al. Current overview on hypercoagulability in COVID-19. Am J Cardiovasc Drugs 2020;20:393–403.
25. Wong GL, Wong VW, Thompson A, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol 2020;5:776–787.
26. Zhong P, Xu J, Yang D, et al. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. Signal Transduct Target Ther 2020;5:256.
27. Grein J, Myers RP, Brainard D. Compassionate use of remdesivir in COVID-19. Reply. N Engl J Med 2020;382:e101.

Reprint requests
Address requests for reprints to: Guadalupe Garcia-Tsao, MD, VA—Connecticut Healthcare, 950 Campbell Avenue, West Wing, West Haven, Connecticut 06516. e-mail: guadalupe.garcia-tsao@yale.edu; fax: (203) 937-3868.

CRediT Authorship Contributions
Michael Chew, MD (Conceptualization: Equal; Data curation: Lead; Formal analysis: Supporting; Investigation: Lead; Methodology: Lead; Project administration: Lead; Supervision: Supporting; Validation: Equal; Writing – original draft: Equal; Writing – review & editing: Equal)
Zeyu Tang (Conceptualization: Equal; Data curation: Lead; Investigation: Supporting; Methodology: Supporting; Project administration: Equal; Software: Lead; Validation: Lead; Writing – review & editing: Supporting)
Christopher Radcliffe (Conceptualization: Supporting; Data curation: Equal; Methodology: Equal; Validation: Equal; Writing – review & editing: Supporting)
Dennis Caruana (Conceptualization: Supporting; Data curation: Supporting; Methodology: Supporting; Validation: Equal; Writing – review & editing: Supporting)
Natty Dollichio (Conceptualization: Supporting; Data curation: Supporting; Methodology: Supporting; Validation: Supporting)
Maria M. Ciarlegio (Conceptualization: Supporting; Formal analysis: Lead; Methodology: Equal; Validation: Equal; Writing – review & editing: Supporting)
Yanhong Deng (Conceptualization: Equal; Formal analysis: Lead; Methodology: Equal; Validation: Lead; Writing – review & editing: Supporting)
Guadalupe Garcia-Tsao (Conceptualization: Lead; Data curation: Supporting; Formal analysis: Equal; Funding acquisition: Lead; Investigation: Lead; Methodology: Lead; Project administration: Lead; Resources: Lead; Supervision: Lead; Validation: Equal; Visualization: Equal; Writing – original draft: Lead; Writing – review & editing: Lead)

Conflicts of interest
The authors disclose no conflicts.

Funding
Supported by the Yale Liver Center National Institutes of Health grant P30 DK34989.
YNHHS Initial Treatment Algorithm for Hospitalized ADULTS with Non-Severe* COVID-19

Disclaimer: There are no FDA-approved treatments for COVID-19, supportive care is standard of care. Limited treatment data are available & clinical judgment is warranted – Algorithm last updated 4/27/20.

Assess all patients routinely for clinical trial eligibility (see Appendix 6)
*If mechanically ventilated or on ECMO, proceed to Severe algorithm

A-Presence of:
Oxygen saturation ≤ 93% on room air OR on chronic O₂ supplementation (if O₂ ≥ 93% see box B)

YES

START TREATMENT (see treatment below)

SUPPORTIVE CARE & EVERY 4 HOUR OXYGEN MONITORING

NO

If Oxygen saturation ≤ 93% on room air
* For pregnant women, O₂ sat ≤ 95%

B-Presence of:
1) Fever and/or signs & symptoms of respiratory disease (e.g. cough, dyspnea) OR
2) Chest X-Ray showing lung opacities

YES

Does patient have:
Age ≥ 60 OR
BMI ≥ 30 OR
Diabetes (HgbA1c ≥ 8.0) OR
Chronic heart disease/HTN OR
Chronic lung disease OR
Immunosuppressed*

YES

START TREATMENT

TREATMENT
Start hydroxychloroquine x 5 days

If ≥ 3 Liter O₂ requirement
OR ≥ 2 Liter O₂ requirement & hs-CRP >70
Consider tocilizumab
(see Appendix 1 for exclusion criteria)

Consider MICU evaluation if > 4 Liter O₂ requirement or hemodynamic instability
(at YNH see Appendix 2 for suggested triage guidelines)

YNHH: ID consult is not mandatory; consider ID input if immunosuppressed* or clinically decompensating
BH, GH, LMH, or Wt: consult ID

See Page 3 of algorithm for multi-disciplinary management by sub-specialty recommendations

Report suspected adverse events related to therapeutics through RL solutions

COVID-SPECIFIC TESTS
1) Baseline & every 12 hours (for 5 days, then daily thereafter): CRP, D-dimer
2) Baseline & every 12 hours x3: Troponin (continue longer if further testing clinically indicated)
3) Baseline & every 24 hours (for 5 days*): CBC with differential, CMP, Ferritin, Procalcitonin, BNP, fibrinogen, PT/PTT, Mg
4) Baseline & ICU transfer: Cytokine panel
5) Baseline and with acute kidney injury (AKI): urinalysis and urine protein/albumin ratio
6) Baseline EKG, and if not on telemetry, daily EKG x 3. (see Appendix 3 for CTV recommendations)
7) Repeat Chest X-Ray: if clinical deterioration. (CXR not indicated for discharge or to document clinical improvement)
*May extend longer if clinically indicated

Algorithm reviewed by YNHHS SAS and YNH/NYS Ad-Hoc COVID-19 Treatment Team
Supplementary Figure 1. Treatment algorithm for hospitalized patients with coronavirus-19 disease (COVID-19) at the time of the study. BH, Bridgeport Hospital; BMI, body mass index; BNP, brain natriuretic peptide; CBC, complete blood count; CMP, complete metabolic panel; CRP, C-reactive protein; CXR, chest x-ray; ECMO, extracorporeal membrane oxygenation; EKG, electrocardiogram; FDA, Food and Drug Administration; GH, Greenwich Hospital; HgbA1c, hemoglobin A1c; hs-CRP, high-sensitivity C-reactive protein; HTN, hypertension; ICU, intensive care unit; ID, Infectious Diseases; LMH, Lawrence and Memorial Hospital; MICU, Medical Intensive Care Unit; PCR, polymerase chain reaction; PT, prothrombin time; PTT, partial thromboplastin time; Q8H, every 8 hours; QTc, correct QT interval; RL, Radiologic Technologies; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SAS, staff and associate specialist; WH, Westerly Hospital; YNHH, Yale New Haven Hospital; YNHHS, Yale New Haven Hospital System; YSM, Yale School of Medicine.
Supplementary Figure 2. Log aspartate aminotransferase (AST) values in 29 patients at 3 different time periods: up to 2 days before vasopressor use, during vasopressor use, and up to 4 days after vasopressor discontinuation.

Supplementary Table 1. Laboratory Reference Ranges

| Laboratory value                        | Reference range                                      |
|-----------------------------------------|------------------------------------------------------|
| Total bilirubin                         | ≤1.2 mg/dL                                           |
| Alkaline phosphatase                    | ≤122 U/L                                             |
| Aspartate aminotransferase              | ≤33 U/L                                              |
| Alanine aminotransferase                | ≤34 U/L                                              |
| Albumin                                 | >3.5 g/dL                                            |
| High-sensitivity C-reactive protein, mg/L| <1.0: lower relative cardiovascular risk              |
|                                         | 1.0–3.0: average relative cardiovascular risk        |
|                                         | 3.1–10.0: higher relative cardiovascular risk         |
|                                         | >10.0: persistent increase may be associated with infection and inflammation |
| Ferritin                                | ≤400 ng/dL                                           |
| Fibrinogen                              | ≤464 mg/dL                                           |
| D-dimer (mg/L)                          | ≤0.68 mg/L                                           |
| IL6                                     | ≤5 pg/mL                                              |
| IL8                                     | ≤5 pg/mL                                              |
| IL1β                                    | ≤36 pg/mL                                             |
| Interferon-γ                            | ≤5 pg/mL                                              |
| TNF-α                                   | ≤22 pg/mL                                             |

IL, interleukin; TNF, tumor necrosis factor.
Supplementary Table 3. Admission Liver Tests by Degree of Abnormality in 834 Patients Admitted With Coronavirus-19 Disease

| Variables | Total (N = 834) |
|-----------|----------------|
| **AST, N (%)** |                  |
| Normal     | 313 (37.5)      |
| 1–2× ULN   | 347 (41.6)      |
| 2–5× ULN   | 149 (17.9)      |
| ≥5× ULN    | 25 (3.0)        |
| AST >5× ULN anytime | 105 (12.6)     |
| **ALT, N (%)** |                  |
| Normal     | 553 (66.3)      |
| 1–2× ULN   | 185 (22.2)      |
| 2–5× ULN   | 83 (9.9)        |
| ≥5× ULN    | 13 (1.6)        |
| ALT >5× ULN anytime | 93 (11.1)     |
| **Total bilirubin, N (%)** |                |
| Normal     | 808 (96.9)      |
| 1–2× ULN   | 22 (2.6)        |
| 2–5× ULN   | 4 (0.5)         |
| ≥5× ULN    | 0              |
| **Alkaline phosphatase, N (%)** |            |
| Normal     | 735 (88.1)      |
| 1–2× ULN   | 84 (10.1)       |
| 2–5× ULN   | 14 (1.7)        |
| ≥5× ULN    | 1 (0.1)         |
| **Albumin, mg/dL, N = 831** |          |
| 3.5 (1.7–5.4) | 3.5 (1.7–5.4) |
| Normal, N (%) | 721 (87.4)    |
| 1–2× ULN, N (%) | 90 (10.9)     |
| 2–5× ULN, N (%) | 7 (0.8)       |
| ≥5× ULN, N (%) | 7 (0.8)       |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; ULN, upper limit of normal.

Supplementary Table 4. Multivariate Model for Death Using AST Excluding 46 Patients Without Follow-Up Evaluation

| Variables | OR  | 95% CI    | P value |
|-----------|-----|-----------|---------|
| Age       | 1.1 | 1.0–1.1   | <.0001  |
| Sex       | 1.6 | 1.0–2.6   | .05     |
| Race      | 0.8 | 0.4–1.4   | .7      |
| BMI       | 1.0 | 0.9–1.0   | .8      |
| Hypertension | 0.9 | 0.5–1.8   | .8      |
| Congestive heart failure | 0.9 | 0.5–1.6   | .8      |
| Chronic lung disease | 0.6 | 0.4–1.1   | .1      |
| Diabetes  | 1.0 | 0.6–1.6   | 1.0     |
| Pre-existing liver disease | 0.8 | 0.3–2.1   | .6      |
| Vasopressor | 5.1 | 2.8–9.4   | <.0001  |
| Tocilizumab use | 1.5 | 0.8–2.7   | .1      |
| Hyperinflammatory | 1.5 | 0.9–2.7   | .1      |
| Hypercoagulable | 1.5 | 0.9–2.5   | .1      |
| ALT >5× ULN | 1.2 | 0.5–2.6   | .6      |
| Steroids  | 1.9 | 1.1–3.2   | .01     |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; OR, odds ratio; ULN, upper limit of normal.

Supplementary Table 5. Multivariate Analysis for Predictors of ALT Level >5× ULN

| Characteristic | Odds ratio | 95% CI    | P value |
|---------------|------------|-----------|---------|
| Tocilizumab   | 3.8        | 1.9–7.7   | .0002   |
| Ischemia      | 3.2        | 1.8–5.6   | <.0001  |
| Hyperinflammatory | 1.4 | 0.8–2.4   | .2      |
| Hypercoagulable | 1.0 | 0.6–1.7   | .9      |
| Steroids      | 1.0        | 0.6–1.7   | .9      |

ALT, alanine aminotransferase; ULN, upper limit of normal.
### Supplementary Table 6. Baseline Characteristics Associated With Death Using AST Value

| Characteristic                          | Overall (834) | Alive (N = 698) | Dead (N = 136) | $P$ value | Univariate Odds ratio | 95% CI | $P$ value | Multivariate Odds ratio | 95% CI | $P$ value |
|----------------------------------------|---------------|----------------|----------------|-----------|-----------------------|--------|-----------|-------------------------|--------|-----------|
| Age, y                                  | 68 (20–103)   | 66 (20–98)     | 82 (29–103)    | <.001     | 1.1                   | 1.0–1.1 | <.0001    |                         |        |           |
| Sex                                     |               |                |                |           |                       |        |           |                         |        |           |
| Male, %                                 | 47.6          | 46.5           | 52.9           |           | .2                    |         | 1.5       | 0.9–2.3                 | .1      |           |
| Female, %                               | 52.4          | 53.4           | 47.1           |           |                       |        |           |                         |        |           |
| Race, N (%)                             |               |                |                | .04       | 0.8                   | 0.4–1.3 | .6        |                         |        |           |
| White                                   | 459 (55)      | 53.3           | 63.9           |           |                       |        |           |                         |        |           |
| Black                                   | 240 (28.8)    | 30.1           | 22.1           |           |                       |        |           |                         |        |           |
| Asian or Pacific Islander               | 14 (1.7)      | 1.7            | 1.5            |           |                       |        |           |                         |        |           |
| Other                                   | 121 (14.5)    | 14.9           | 12.5           |           |                       |        |           |                         |        |           |
| Median BMI, kg/m² (range)               | 28.2 (14.6–73.9) | 28.4 (14.6–73.9) | 26.1 (15–64.8) | <.001     | 1.0                   | 0.9–1.0 | .9        |                         |        |           |
| Comorbidities, N (%)                    |               |                |                |           |                       |        |           |                         |        |           |
| Coronary artery disease                 | 97 (13.5)     | 80 (13.5)      | 17 (13.9)      | .9        |                       |        |           |                         |        |           |
| Hypertension                            | 631 (75.6)    | 519 (74.4)     | 112 (82.3)     | .05       | 0.8                   | 0.4–1.6 | .6        |                         |        |           |
| Congestive heart failure                | 249 (29.8)    | 201 (28.8)     | 48 (35.3)      | .1        | 0.9                   | 0.5–1.5 | .7        |                         |        |           |
| Chronic lung disease                    | 277 (33.2)    | 237 (33.9)     | 40 (29.4)      | .3        | 0.6                   | 0.4–1.1 | .1        |                         |        |           |
| Diabetes                                | 357 (42.8)    | 293 (42.0)     | 64 (47.1)      | .3        | 1.1                   | 0.7–1.8 | .6        |                         |        |           |
| Pre-existing liver disease, N (%)       | 51 (6.1)      | 45 (6.4)       | 6 (4.4)        | .4        | 0.9                   | 0.3–2.5 | .8        |                         |        |           |
| Compensated cirrhosis                   | 10 (1.2)      | 8 (1.1)        | 2 (1.5)        | .5        |                       |        |           |                         |        |           |
| Decompensated cirrhosis                | 3 (0.3)       | 2 (0.3)        | 1 (0.7)        | .4        |                       |        |           |                         |        |           |
| Tocilizumab                             | 502 (60.2)    | 406 (58.2)     | 96 (70.6)      | .007      | 1.2                   | 0.7–2.0 | .6        |                         |        |           |
| Steroid                                 | 273 (32.7)    | 207 (29.6)     | 66 (48.5)      | <.001     | 1.8                   | 1.1–2.9 | .02       |                         |        |           |
| Ischemia                                | 102 (12.2)    | 69 (9.9)       | 33 (24.3)      | <.001     | 5.0                   | 2.8–9.3 | <.0001    |                         |        |           |
| Hyperinflammatory                       | 484 (58.4)    | 383 (55.0)     | 101 (76.0)     | <.001     | 1.8                   | 1.1–3.0 | .02       |                         |        |           |
| Hypercoagulable                         | 251 (30.6)    | 186 (27.0)     | 65 (50.0)      | <.001     | 1.4                   | 0.9–2.3 | .7        |                         |        |           |
| AST, >5 × ULN                           | 105 (12.6)    | 84 (12.0)      | 21 (15.4)      | .3        | 0.9                   | 0.4–1.7 | .7        |                         |        |           |

AST, aspartate aminotransferase; BMI, body mass index; ULN, upper limit of normal.
Supplementary Table 7. Multivariate Model for Death Using ALT

| Variables                  | OR   | 95% CI    | P value |
|----------------------------|------|-----------|---------|
| Age                        | 1.1  | 1.0–1.1   | <.0001  |
| Sex                        | 1.5  | 0.9–2.3   | .1      |
| Race                       | 0.7  | 0.4–1.3   | .6      |
| BMI                        | 1.0  | 0.9–1.0   | .9      |
| Hypertension               | 0.8  | 0.4–1.6   | .6      |
| Congestive heart failure   | 0.9  | 0.5–1.5   | .7      |
| Chronic lung disease       | 0.6  | 0.4–1.1   | .1      |
| Diabetes                   | 1.1  | 0.7–1.7   | .7      |
| Pre-existing liver disease | 0.9  | 0.3–2.4   | .8      |
| Vasopressor requirement    | 5.2  | 2.9–9.5   | <.0001  |
| Tocilizumab use            | 1.1  | 0.7–2.0   | .5      |
| Any inflammatory           | 1.8  | 1.1–3.1   | .02     |
| Any hypercoagulable        | 1.4  | 0.8–2.3   | .14     |
| Peak ALT value             | 1.1  | 0.5–2.2   | .8      |
| Steroids                   | 1.7  | 1.0–2.9   | .02     |

ALT, alanine aminotransferase; BMI, body mass index; OR, odds ratio.
### Supplementary Table 8. Characteristics of 8 of 105 (7.6%) Patients Who Developed Liver Insufficiency During COVID-19

| ID  | Peak AST | Peak ALT | Peak TBIL | Peak AP | Peak INR | sCr     | Comments |
|-----|----------|----------|-----------|---------|----------|---------|----------|
| 1   | 3663     | 2157     | 2.6       | 174     | 3.73     | 6.0     | 66-year-old with severe COVID-19 requiring intubation  
COVID Tx: hydroxychloroquine, tocilizumab  
Antibiotics: ceftriaxone, piperacillin/tazobactam, vancomycin  
Vasopressors: norepinephrine  
Complications: perforated diverticulitis and death |
| 2   | 3054     | 904      | 0.7       | 357     | 4.67     | 1.8     | 42-year-old with severe COVID-19 requiring intubation  
COVID-Tx: hydroxychloroquine, tocilizumab  
Antibiotics: ceftriaxone, doxycycline  
Vasopressors: norepinephrine, epinephrine  
Complications: cardiac arrest with shock and death |
| 3   | 5283     | 2724     | 9.2       | 211     | 2.56     | 1.8     | 29-year-old with severe COVID requiring intubation  
COVID-Tx: hydroxychloroquine, tocilizumab, remdesivir, steroids  
Antibiotics: ceftriaxone, doxycycline  
Vasopressors: norepinephrine, phenylephrine, vasopressin  
Complications: neuroleptic malignant syndrome with fever 108°F and death |
| 4   | 9441     | 3141     | 16.8      | 523     | 1.95     | 3.1     | 64-year-old with history of HIV presented with severe COVID requiring intubation  
COVID-Tx: hydroxychloroquine, tocilizumab, remdesivir, steroids  
Antibiotics: piperacillin/tazobactam, ciprofloxacin, daptomycin  
Vasopressors: norepinephrine, vasopressin, phenylephrine  
Complications: multiple infections and renal failure requiring CVVH and death |
| 5   | 1825     | 1691     | 2.7       | 77      | 3.18     | 6.9     | 74-year-old with severe COVID requiring intubation  
COVID-Tx: hydroxychloroquine, tocilizumab, steroids  
Antibiotics: piperacillin/tazobactam, vancomycin  
Vasopressors: norepinephrine, phenylephrine  
Complications: NSTEMI requiring heparin drip and hemorrhagic shock resulting in death |
| 6   | 1107     | 452      | 3.9       | 339     | 2.08     | 3.8     | 63-year-old severe COVID requiring intubation  
COVID-Tx: tocilizumab, steroids  
Antibiotics: piperacillin/tazobactam  
Vasopressors: norepinephrine, phenylephrine, vasopressin  
Complications: renal failure requiring CVVH and malignant hyperthermia with Tmax 108°F and death |
| 7   | 4221     | 1447     | 1.8       | 209     | 2.3      | 7.1     | 55-year-old severe COVID requiring intubation  
COVID-Tx: hydroxychloroquine, tocilizumab, steroids  
Antibiotics: ceftriaxone, ciprofloxacin, ertapenem  
Vasopressors: norepinephrine, epinephrine, phenylephrine, vasopressin  
Complications: acute kidney injury requiring dialysis and death |
| 8   | 8921     | 5106     | 1         | 228     | 1.89     | 3.2     | 89-year-old severe COVID requiring NRB  
COVID-Tx: Hydroxychloroquine  
Antibiotics: piperacillin/tazobactam  
Vasopressors: none but hypotensive and increasing lactate and transitioned to comfort measures only  
Complications: bacterial pneumonia and multi-organ failure and death |

NOTE. Of the 105 patients with severe liver injury, there were only 8 patients (7.6%) in whom peak AST level was associated with an INR greater than 1.5 (encephalopathy was not evaluable because all patients were sedated).  
AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase; COVID-19, coronavirus-19 disease; CVVH, continuous veno-venous hemofiltration; HIV, human immunodeficiency virus; INR, international normalized ratio; NRB, non-rebreather; NSTEMI, non-ST elevation myocardial infarction; sCr, serum creatinine; TBIL, total bilirubin; Tmax, maximal temperature; Tx, treatment.